ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer scientists have reprogrammed an engineered microbe to improve the fermentation yield of the promising cancer drug thailanstatin A, a crucial step in its further development as a chemotherapy agent (Metab. Eng. 2015, DOI: 10.1016/j.ymben.2015.11.003). Thailanstatin A is a member of the spliceostatin family of bacterial natural products that interact with the spliceosome, the protein-RNA hybrid complex that is responsible for editing mRNA before the ribosome uses it to make proteins. Misregulation of mRNA splicing and mutations in the splicing machinery are associated with several cancers, and spliceostatins can put a halt to the problems. Alessandra S. Eustáquio and colleagues previously developed a biosynthetic pathway to make more potent and stable spliceostatins, but it was limited to producing 60 mg/L of thailanstatin A. The team found a bottleneck in the pathway, which they alleviated by increasing the expression of a gene to improve selective formation of a key hydroxyl group. The reprogramming helped increase production to 2.5 g/L, a level sufficient to support clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter